This second edition of Health at a Glance Asia/Pacific presents a set of key indicators of health status, the determinants of health, health care resources and utilisation, health care expenditure and financing and health care quality across 27 Asia/Pacific countries and economies.
Though the rate of public spending on healthcare in the Asia/Pacific region is still well below the OECD average, countries there are committing more resources to improving health care quality.
English, PDF, 274kb
Background paper for the OECD Expert workshop on improving health expenditure forecasting.
English, PDF, 717kb
Updated, refined and extended projections of public spending on health and long-term care for OECD countries and the BRIICS suggest a rapidly rising trend over the next 50 years.
English, PDF, 66kb
Detailed agenda for the meeting "Informing Policy Makers About Future Health Spending: OECD Expert Workshop on Improving Health Expenditure Forecasting Methods", which took place on 30 November 2012 in Paris.
Health spending fell across the European Union in 2010, as cash-strapped governments curbed outlays to help cut budgetary deficits, according to Health at a Glance: Europe 2012, a new joint report by the OECD and the European Commission.
This workshop will convene leading experts from health and finance backgrounds in government, academia, and international organisations to take stock of progress in health expenditure forecasting and to discuss future directions, in light of policy needs and recent advancements in techniques, detailed data and computing power.
New OECD data show that men are more likely to be admitted to hospital as a result of poor management of diabetes than women, even when there are no significant differences in the number of men and women living with diabetes.
The OECD and the ESRC Genomics Policy & Research Forum jointly organised a one-day Forum on 12 November 2012 in Paris. The event was both retrospective and forward-looking. The forum concluded that the promise of biotechnology is not set but evolves with fresh scientific knowledge, novel laws and regulations. The future of biotechnology needs to also integrate social and cultural dimensions.
Each year about 1.3 million people are killed and another 50 million people are injured on roads worldwide. These road crashes cost countries between 1 and 3 percent of their GDP. Many of these crashes can be prevented by effective countermeasures. This report helps identify the most effective safety countermeasures.
Policy makers need to justify expenditure on road safety in terms of effectiveness, competing for the scarce